The Belgian cell therapy company, TiGenix NV, has appointed Marie Paule Richard as its chief medical officer with responsibility for overseeing development of new therapies for rheumatoid arthritis, fistulas in Crohn’s disease and sepsis. Dr Richard was previously CMO at AiCuris in Germany and before that held executive positions at Crucell (Johnson & Johnson Inc) and Sanofi Pasteur.
Separately, the company also appointed Mary Carmen Diez as vice president for medical affairs and new product commercialisation. Dr Diez joins TiGenix from Meda Pharma AB where she was international medical marketing director.
TiGenix announced the appointments on 1 September 2014.
Copyright 2014 Evernow Publishing Ltd